Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays
- PMID: 15196820
- DOI: 10.1016/j.antiviral.2004.02.006
Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays
Abstract
Human metapneumovirus (hMPV) is a recently elucidated respiratory virus pathogen for which there are no agents currently licensed to prevent or treat infections caused by it. However, NMSO3 has been reported to inhibit replication of human respiratory syncytial virus (hRSV), a virus that is closely related to hMPV, both in vitro in tissue culture cells and in vivo in cotton rats. For this reason, experiments were performed to compare the antiviral activity of NMSO3 against both hRSV and hMPV in tissue culture-based assays. Heparin and ribavirin, two other compounds known to inhibit hRSV, and two other paramyxoviruses, human parainfluenza virus type 3 (PIV3) and measles virus (MV), were included in these tests for comparison. All three compounds significantly inhibited the replication of subtype A and B strains of hRSV and serotypes 1 and 2 hMPV. However, unlike ribavirin, NMSO3 and heparin inhibited only hMPV and hRSV and not PIV3 or MV. Also unlike ribavirin, the activity of the two sulfated molecules was most effective if these materials were present during virus attachment and penetration of host cells. Interestingly, NMSO3, but not heparin, was able to limit secondary infection and spread of both viruses.
Similar articles
-
Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro.Antiviral Res. 2003 Sep;60(1):51-9. doi: 10.1016/s0166-3542(03)00153-0. Antiviral Res. 2003. PMID: 14516921
-
Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo.J Infect Dis. 2004 Apr 15;189(8):1419-30. doi: 10.1086/382958. Epub 2004 Apr 2. J Infect Dis. 2004. PMID: 15073679
-
Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus.Antiviral Res. 2004 Mar;61(3):165-71. doi: 10.1016/j.antiviral.2003.09.008. Antiviral Res. 2004. PMID: 15168797
-
Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection.Virulence. 2017 Aug 18;8(6):685-704. doi: 10.1080/21505594.2016.1265725. Epub 2016 Dec 2. Virulence. 2017. PMID: 27911218 Free PMC article. Review.
-
[Human metapneumovirus--new identified virus infecting human respiratory tract].Przegl Epidemiol. 2004;58(2):325-33. Przegl Epidemiol. 2004. PMID: 15517813 Review. Polish.
Cited by
-
Human metapneumovirus.Clin Lab Med. 2010 Mar;30(1):131-48. doi: 10.1016/j.cll.2009.10.002. Clin Lab Med. 2010. PMID: 20513544 Free PMC article. Review.
-
Effect of NMSO3 treatment in a murine model of human metapneumovirus infection.J Gen Virol. 2008 Nov;89(Pt 11):2709-2712. doi: 10.1099/vir.0.2008/003301-0. J Gen Virol. 2008. PMID: 18931066 Free PMC article.
-
Targeting RSV with vaccines and small molecule drugs.Infect Disord Drug Targets. 2012 Apr;12(2):110-28. doi: 10.2174/187152612800100143. Infect Disord Drug Targets. 2012. PMID: 22335496 Free PMC article. Review.
-
Respiratory viral infections in transplant and oncology patients.Infect Dis Clin North Am. 2010 Jun;24(2):395-412. doi: 10.1016/j.idc.2010.01.007. Infect Dis Clin North Am. 2010. PMID: 20466276 Free PMC article. Review.
-
In vitro anti-HMPV activity of meroditerpenoids from marine alga Stypopodium zonale (Dictyotales).Molecules. 2011 Oct 10;16(10):8437-50. doi: 10.3390/molecules16108437. Molecules. 2011. PMID: 21986522 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources